Neurology:儿童发病的多发性硬化症患者长期残疾进展

2019-05-17 xing.T 网络

由此可见,儿童发病的MS患者遵循独特的临床过程,应该在疾病的治疗和管理中加以考虑。

近日,神经病学领域权威取杂志Neurology上发表了一篇研究文章,研究人员旨在评估儿科发病多发性硬化症(POMS)的长期残疾进展,并与成人发病的多发性硬化症(AOMS)进行比较。

这是一项回顾性队列研究,使用了瑞典MS登记处前瞻性收集的临床信息。研究人员比较了受试者的临床特征,并使用Kaplan-Meier和Cox比例风险回归评估在POMS(多发性硬化[MS]发病<18岁)和AOMS(MS发病≥18岁)中达到持续扩展残疾状态量表(EDSS)3、4和6的风险。 

该研究共纳入了12482名受试者;549人(4.4%)被归类为POMS。POMS队列从MS发病开始到达所有3个残疾里程碑事件需要更长的时间,但是在比AOMS队列更年轻的时候就出现残疾。主要进展过程(风险比[HR]为4.63; 95%置信区间[CI]为1.46-14.7)、前5年较高的疾病复发率(HR为5.35; 95%CI为3.37-8.49)、从初始复发到完全缓解(HR为0.41; 95%CI为0.18-0.94)与POMS病例中进展为EDSS 4的风险改变相关。达到EDSS 3和6的风险也出现了同样的变化模式。

由此可见,儿童发病的MS患者遵循独特的临床过程,应该在疾病的治疗和管理中加以考虑。 

原始出处:

Kyla A. McKay,et al.Long-term disability progression ofpediatric-onset multiple sclerosis.Neurology.2019.https://doi.org/10.1212/WNL.0000000000007647

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2000768, encodeId=82622000e683b, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Oct 18 02:07:00 CST 2019, time=2019-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983066, encodeId=09441983066b1, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Mon Aug 05 16:07:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969597, encodeId=80df196959eea, content=<a href='/topic/show?id=89326345995' target=_blank style='color:#2F92EE;'>#残疾进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63459, encryptionId=89326345995, topicName=残疾进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55f6293, createdName=lishizhe, createdTime=Mon Oct 07 14:07:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890008, encodeId=47e718900087d, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Fri Dec 20 08:07:00 CST 2019, time=2019-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366357, encodeId=536536635e9b, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Fri May 17 14:43:07 CST 2019, time=2019-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366350, encodeId=919236635017, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri May 17 12:50:05 CST 2019, time=2019-05-17, status=1, ipAttribution=)]
    2019-10-18 yinhl1978
  2. [GetPortalCommentsPageByObjectIdResponse(id=2000768, encodeId=82622000e683b, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Oct 18 02:07:00 CST 2019, time=2019-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983066, encodeId=09441983066b1, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Mon Aug 05 16:07:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969597, encodeId=80df196959eea, content=<a href='/topic/show?id=89326345995' target=_blank style='color:#2F92EE;'>#残疾进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63459, encryptionId=89326345995, topicName=残疾进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55f6293, createdName=lishizhe, createdTime=Mon Oct 07 14:07:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890008, encodeId=47e718900087d, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Fri Dec 20 08:07:00 CST 2019, time=2019-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366357, encodeId=536536635e9b, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Fri May 17 14:43:07 CST 2019, time=2019-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366350, encodeId=919236635017, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri May 17 12:50:05 CST 2019, time=2019-05-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2000768, encodeId=82622000e683b, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Oct 18 02:07:00 CST 2019, time=2019-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983066, encodeId=09441983066b1, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Mon Aug 05 16:07:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969597, encodeId=80df196959eea, content=<a href='/topic/show?id=89326345995' target=_blank style='color:#2F92EE;'>#残疾进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63459, encryptionId=89326345995, topicName=残疾进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55f6293, createdName=lishizhe, createdTime=Mon Oct 07 14:07:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890008, encodeId=47e718900087d, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Fri Dec 20 08:07:00 CST 2019, time=2019-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366357, encodeId=536536635e9b, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Fri May 17 14:43:07 CST 2019, time=2019-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366350, encodeId=919236635017, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri May 17 12:50:05 CST 2019, time=2019-05-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2000768, encodeId=82622000e683b, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Oct 18 02:07:00 CST 2019, time=2019-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983066, encodeId=09441983066b1, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Mon Aug 05 16:07:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969597, encodeId=80df196959eea, content=<a href='/topic/show?id=89326345995' target=_blank style='color:#2F92EE;'>#残疾进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63459, encryptionId=89326345995, topicName=残疾进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55f6293, createdName=lishizhe, createdTime=Mon Oct 07 14:07:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890008, encodeId=47e718900087d, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Fri Dec 20 08:07:00 CST 2019, time=2019-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366357, encodeId=536536635e9b, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Fri May 17 14:43:07 CST 2019, time=2019-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366350, encodeId=919236635017, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri May 17 12:50:05 CST 2019, time=2019-05-17, status=1, ipAttribution=)]
    2019-12-20 jml2009
  5. [GetPortalCommentsPageByObjectIdResponse(id=2000768, encodeId=82622000e683b, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Oct 18 02:07:00 CST 2019, time=2019-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983066, encodeId=09441983066b1, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Mon Aug 05 16:07:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969597, encodeId=80df196959eea, content=<a href='/topic/show?id=89326345995' target=_blank style='color:#2F92EE;'>#残疾进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63459, encryptionId=89326345995, topicName=残疾进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55f6293, createdName=lishizhe, createdTime=Mon Oct 07 14:07:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890008, encodeId=47e718900087d, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Fri Dec 20 08:07:00 CST 2019, time=2019-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366357, encodeId=536536635e9b, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Fri May 17 14:43:07 CST 2019, time=2019-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366350, encodeId=919236635017, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri May 17 12:50:05 CST 2019, time=2019-05-17, status=1, ipAttribution=)]
    2019-05-17 龙胆草

    学习谢谢分享

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2000768, encodeId=82622000e683b, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Oct 18 02:07:00 CST 2019, time=2019-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983066, encodeId=09441983066b1, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Mon Aug 05 16:07:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969597, encodeId=80df196959eea, content=<a href='/topic/show?id=89326345995' target=_blank style='color:#2F92EE;'>#残疾进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63459, encryptionId=89326345995, topicName=残疾进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55f6293, createdName=lishizhe, createdTime=Mon Oct 07 14:07:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890008, encodeId=47e718900087d, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Fri Dec 20 08:07:00 CST 2019, time=2019-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366357, encodeId=536536635e9b, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Fri May 17 14:43:07 CST 2019, time=2019-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366350, encodeId=919236635017, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri May 17 12:50:05 CST 2019, time=2019-05-17, status=1, ipAttribution=)]
    2019-05-17 1ddf0692m34(暂无匿称)

    学习了,长知识

    0

相关资讯

Int J Rheum Dis:儿童期发病的系统性红斑狼疮的生存率的影响因素有哪些?

背景:儿童期发病的系统性红斑狼疮(cSLE)占的SLE患者的15-20%。尽管一些研究报道成人SLE预后,鲜有对中东地区cSLE的调查研究。方法:这项回顾性的研究,招募1992年到2011年患有系统性红斑狼疮的孩子。记录和分析疾病开始时间点的临床和实验室数据。应用Kalpan-Meier计算生存率。应用Cox回归分析评估死亡的预测因子。结果:研究期间,招募了188名诊断为SLE的儿童。9名患者排除